Shuchi Nahar's Weekend Blog!

India Emerging as a Next Biologic Drug Hub SHUCHI.P.NAHAR The Indian pharmaceutical companies always had strong chemistry skills to work on small molecules to make generic drugs, but they lacked skills, people and ecosystem to work on large molecules to come up with reverse engineered versions of biotech drugs, many experts complain. However, it is beginning to change.   'India: the emerging hub for biologics and biosimilars', the Indian pharmaceutical companies have launched 123 biosimilars and currently have 201 active biosimilars covering multiple indications in the development pipeline. Further, India has 95 approved biosimilars in the domestic market, more than any other country in the world. Biologics are the biological products regulated under the rules of the Food and Drug Administration (FDA). They are used to either diagnose, prevent, treat, or cure various medical conditions.  Significantly, biologics are large, complex, and diverse molecules produced through biotech

Emerging Trends in Animal Health Care Industry SHUCHI.P.NAHAR Just like the world around us, animal health has undergone transformational change in the 21st century. Animals are receiving better care, medicines are becoming more targeted, and diseases have even been eradicated. There's no sign that this change will stop soon. Here are the four trends that will drive animal agriculture and petcare in the coming years.The niche global animal health sector is witnessing exciting growth opportunities and consolidation. On the one hand, the opportunity landscape is driven by population expansion, increased demand for animal protein, changing lifestyles and evolving habits. On the other hand, the consolidation is the result of growing compliance and complexity. The global animal health market size was valued at USD 47.1 billion in 2019 and is expected to exhibit a CAGR of 5.8% during the forecast period. The market is largely driven by a significant rise in demand for protein food and an

CDMO's to be considered as the next stepping stone for Pharma Companies... Twitter Handle: @shuchi_nahar In recent years, pharmaceutical outsourcing has grown in popularity amongst drug developers across the industry. Companies are increasingly outsourcing to contract development and manufacturing organizations (CDMOs) due to the benefits outside expertise can bring to their business. So, what are the benefits and how are current CDMO market trends shaping? Pharma CDMO's Trends The pharmaceutical industry is expected to be worth $1.5 trillion by 2021. The key trends driving this level of demand for pharmaceutical products include the world’s aging population, rising healthcare standards in developing countries, and expensive breakthrough therapies. This rapid influx of demand means that companies are faced with higher R&D costs and a need to invest in new capabilities. The demand for healthcare and innovative solutions is growing globally with chronic diseases on the rise.

Pros and Cons of Index Investing -  By Late Mr. Parag Parikh Shuchi.P.Nahar Index funds are simply mutual funds that attempt to mimic a given market. There are actually many more than that tracking many different markets of all shapes and sizes, but each one shares the same basic principle: Its goal is simply to match that particular market’s return. Index investing is therefore simply the process of using index funds to build a passive investment strategy. Index investors decide which markets they want to invest in, how much of their money to put in each one, and utilize index funds to put that plan in place. What is market? Where do you see the market going? how is market judged? By what the index is judged? These are some of the basic questions that every investor asks sooner or later in his investment journey .   If the index is up that means that the market is up, sometimes you may find the market is going up but your portfolio has not increased or decreased. This was